Hui Li

Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial

G. Comi, C. Palermo, M. Pane, 2022, The Lancet Neurology.

Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial

G. Comi, S. Corti, E. Mazzone, 2022, The Lancet Neurology.

Spinal muscular atrophy with hypoplasia of the corpus callosum: a case report

Shuizhen Zhou, Wenhui Li, Yi Wang, 2023, BMC Neurology.

Cross-cultural Adaptation and Multi-centric Validation of the Motor Function Measure Chinese Version (MFM-32-CN) for Patients with Neuromuscular Diseases

Wenzhu Li, C. Vuillerot, Lun Qin, 2020, Developmental neurorehabilitation.

Safety analysis of laboratory parameters in paediatric patients with spinal muscular atrophy treated with nusinersen

Chaoping Hu, Hui Li, Xiao-mei Zhu, 2024, BMC pediatrics.